TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

7885.56USWO

U.S. APPLICATION NO. (if known) (35 U.S.C. 1.5)

09/125953

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/NO97/00083

March 25, 1997

March 26, 1996

TITLE OF INVENTION

IMMUNO-MAGNETIC CELL SEPARATION USED IN IDENTIFICATION OF GENES ASSOCIATED WITH SITE-PREFERENCED CANCER METASTASIS FORMATION

APPLICANT(S) FOR DO/EO/US

Oystein FODSTAD; Johannes Eivind HOVIG; Olav ENGEBRATEN; Anne Hansen REE

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An unsigned oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: International Preliminary Examination Report

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FODSTAD et al.
 Docket: 7885.56USWO
 Title: IMMUNO-MAGNETIC CELL SEPARATION USED IN IDENTIFICATION OF GENES
 ASSOCIATED WITH SITE-PREFERENCED CANCER METHASTASIS FORMATION

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL039318418US

Date of Deposit: August 26, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By: 

Name: Mark Green

BOX PATENT APPLICATION
 Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.
- ☒ National Stage PCT Patent Application: Spec. 7 pgs; 11 claims; Abstract 1 pgs.
 The fee has been calculated as shown below in the 'Claims as Filed' table.
- ☒ Small entity status will be established at a later date
- ☒ An unsigned Combined Declaration and Power of Attorney
- ☒ A check in the amount of \$1070.00 to cover the Filing Fee
- ☒ Other: International Preliminary Examination Report; Preliminary Amendment; Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
- ☒ Return postcard

CLAIMS AS FILED

Number of Claims Filed		In Excess of:		Number Extra		Rate		Fee
Basic Filing Fee								\$1070.00
Total Claims								
11	-	20	=	0	x	11.00	=	\$0.00
Independent Claims								
1	-	3	=	0	x	41.00	=	\$0.00
MULTIPLE DEPENDENT CLAIM FEE								\$0.00
TOTAL FILING FEE								\$1070.00

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT, GOULD, SMITH, EDELL,

WELTER & SCHMIDT

3100 Norwest Center, Minneapolis, MN 55402
 (612) 332-5300

By: 

Name: Michael B. Lasky

Reg. No.: 29,555

Initials: MBL/sef

09/125953

305 Rec'd PCT/PTO 26 AUG 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FODSTAD et al. Docket No.: 7885.56USWO
Serial No.: Unknown Filed:
Int'l Appln No.: PCT/NO97/00083 Int'l Filing Date: March 25, 1997
Title: IMMUNO-MAGNETIC CELL SEPARATION USED IN
IDENTIFICATION OF GENES ASSOCIATED WITH SITE-
PREFERENCED CANCER METASTASIS FORMATION

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EL039318418US

Date of Deposit: August 26, 1998

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

By: 

Name: Mark Green

PRELIMINARY AMENDMENT

Box PCT
Assistant Commissioner for Patents
Washington, D. C. 20231

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment:

IN THE ABSTRACT

Insert the attached Abstract page into the application as the last page thereof.

IN THE SPECIFICATION

A courtesy copy of the originally-filed PCT specification is enclosed herewith, but the World Intellectual Property Office (WIPO) copy should be relied upon if it is already in the U.S. Patent Office.

IN THE CLAIMS

In claim 3, line 1, delete "claims 1-2" and insert --claim 1--.

In claim 4, line 1, delete "claims 1-2" and insert --claim 1--.

In claim 5, line 1, delete "claims 1-4" and insert --claim 1--.

In claim 7, line 1, delete "the above claims" and insert --claim 1--.

In claim 9, lines 3 to 4, delete "described in claims 1-4".

In claim 10, line 1, delete "the preceding claims" and insert --claim 1--.

REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 3 to 5, 7 and 10.

A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.


If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicant's primary attorney-of record, Michael B. Lasky (Reg. No. 29,555), at (612) 336-4634.

Respectfully submitted,

MERCHANT, GOULD, SMITH, EDELL,
WELTER, & SCHMIDT, P.A.
3100 Norwest Center
90 South Seventh Street
Minneapolis, Minnesota 55402
(612) 332-5300

Dated: August 26, 1998

By



Michael B. Lasky
Reg. No. 29,555

MBL/sef

Method for identifying genes with site specific or site preferred expression in target cells that are initially detected and isolated by repeated immuno-magnetic procedures. The purified target cells are then exposed to known cloning procedures. Preferred target cells are malignant cells, e.g. metastatic cells. Gene cloning methods may include the differential display or subtractive hybridization approaches.

Food 4 TV

INDEPENDENT INVENTOR(S)

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 C.F.R. 1.9(f) AND 1.27(b)) - INDEPENDENT INVENTOR**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 C.F.R. 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled IMMUNO-MAGNETIC CELL SEPARATION USED IN IDENTIFICATION OF GENES ASSOCIATED WITH SITE-PREFERENCED CANCER METASTASIS FORMATION described in

- a) ☐ the specification filed herewith.
b) ☐ provisional application serial no. _____, filed _____.
c) ☒ non-provisional application serial no. PCT/NO97/00083, filed Intl Filing Date March 25, 1997.
d) ☐ patent no. _____, issued _____.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 C.F.R. 1.9(c) if that person has made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. 1.9(d) or a nonprofit organization under 37 C.F.R. 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- a) ☐ no such person, concern, or organization
b) ☒ persons, concerns or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 C.F.R. 1.27)

NAME Oystein Fodstad
ADDRESS Frits Kiaers v. 28, N-0383 Oslo Norway
a) ☒ INDIVIDUAL b) ☐ SMALL BUSINESS CONCERN c) ☐ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
a) ☐ INDIVIDUAL b) ☐ SMALL BUSINESS CONCERN c) ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereof, or any patent to which this verified statement is directed.

Oystein Fodstad
NAME OF INVENTOR
[Signature]
Signature of Inventor
23/6-98
Date

Johannes Eivind Hovig
NAME OF INVENTOR
[Signature]
Signature of Inventor
23/6-98
Date

Olav Engebraten
NAME OF INVENTOR
[Signature]
Signature of Inventor
24/6-98
Date

INDEPENDENT INVENTOR(S)

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 C.F.R. 1.9(f) AND 1.27(b)) - INDEPENDENT INVENTOR

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 C.F.R. 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled IMMUNO-MAGNETIC CELL SEPARATION USED IN IDENTIFICATION OF GENES ASSOCIATED WITH SITE-PREFERENCED CANCER METHASTASIS FORMATION described in

- a) ☐ the specification filed herewith.
b) ☐ provisional application serial no. _____, filed _____.
c) ☒ non-provisional application serial no. PCT/NO97/00083, filed Intl Filing Date March 25, 1997.
d) ☐ patent no. _____, issued _____.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 C.F.R. 1.9(c) if that person has made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. 1.9(d) or a nonprofit organization under 37 C.F.R. 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- a) ☐ no such person, concern, or organization
b) ☒ persons, concerns or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 C.F.R. 1.27)

NAME Oystein Fodstad
ADDRESS Frits Kiaers v. 28, N-0383 Oslo Norway
a) ☒ INDIVIDUAL b) ☐ SMALL BUSINESS CONCERN c) ☐ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
a) ☐ INDIVIDUAL b) ☐ SMALL BUSINESS CONCERN c) ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereof, or any patent to which this verified statement is directed.

<u>Anne Hansen Ree</u> NAME OF INVENTOR <u>Anne Hansen Ree</u> Signature of Inventor <u>24/9-98</u> Date	_____ NAME OF INVENTOR _____ Signature of Inventor _____ Date	_____ NAME OF INVENTOR _____ Signature of Inventor _____ Date
---	--	--

(Immuno-Magnetic cell separation used in identification
of genes associated with site-preferenced cancer
methastasis formation.

5 The object of the present invention is to provide a novel approach for detecting new genes with site-specific expression patterns in tumor cells residing in different tissues.

10 It is well known that many cancer types show typical patterns of spread, in that metastases appear preferably in certain tissues or organs, often in an orderly fashion. Thus, breast cancer metastases usually first develop in axillary lymph nodes, whereas bone marrow/bone metastases represent the first and most common (50%) site of distant spread. Of other tissues, liver, lung and the central nervous system (up to 20%) become hosts of breast cancer metastases. Similarly, prostate cancer gives skeletal metastases; colon cancer spreads to lymph nodes and liver; 15 osteosarcoma to lung; and malignant melanoma to lymph nodes, liver, lung and brain. Very little is known about the factors that determine such tissue-preferenced cancer spread, but specific characteristics of the tumor cells are certainly involved, by e.g. enabling the tumor cells to home in the target organ, move to and invade the host tissue, respond to local growth factors, induce angiogenesis, or react in hitherto unknown ways. These characteristics must be associated with expression 20 of specific proteins expressed by known or unknown genes. To identify such genes may, therefore, be of great importance in the understanding of the mechanisms of metastasis and thereby provide new leads or clues for diagnosis and therapy.

25 Several methods are being used in the search for genes that are highly expressed in certain populations of cells and not in other, including procedures such as subtractive hybridization cloning and the use of the differential display approach. Most such cloning projects have involved the use of *in vitro* cell lines or clones as starting material. However, it is known that cell lines may differ significantly from 30 the tumor cells from which they originated, and that *in vitro* culture conditions may up- or down-regulate the expression of genes involved in deciding the ability of the cells to invade extracellular matrices and stromal tissue as well as their overall metastatic capacity.

35 A logical alternative to cell lines for comparing the expression of gene transcripts or proteins of interest would be to use specimens of tumor tissue from primary tumors and metastases from patients. Such an approach does, however, include several possibilities for error and also technical difficulties. When using tumor cells from different patients the expression of genes characteristic of each

individual must be subtracted before the patterns of gene expression related to the objective of the study are compared. This adds to the immense complexity of such gene cloning. It would be advantageous, therefore, to be able to compare expression patterns in cancer cells obtained from tumor manifestations located at different sites in one and the same individual. This may be possible by collecting tumor tissue from both the primary tumor and overt metastases detected and removed at surgery, and/or by surgery or biopsy of recurrent disease, or from secondary tumors in patients with progressive disease who have or have not received other treatment modalities after primary surgery.

In any gene cloning project it is important to work with as pure populations of target cells as possible, attempting to avoid irrelevant signals from non-target cells blurring the expression patterns to be compared. In specimens from solid tumors this is difficult to achieve, as in surgical specimens and biopsies the tumor cells will be mixed with normal fibrous tissue, including stromal and endothelial cells, that conventional methods of tissue preparation cannot satisfactorily remove. In hematological cancers, the malignant cells share determinants of a corresponding subpopulation of normal cells, preventing separation of the two types of cells.

In attempts to identify genes that are involved in the early stages of tumor dissemination, it would be important to obtain tumor cells from the relevant sites when the size of the secondary tumors is small, or if possible even from subclinical tumor foci or cells. One example would be malignant cells present in blood or in bone marrow before conventional diagnostic measures can demonstrate solid manifestation of metastasis. Another example would be cancer cells present in cerebrospinal fluid, in urine, or in effusions in pleural and abdominal cavities before conventional morphological procedures can detect such cells. Moreover, at primary surgery or if suspected for metastatic spread, lymph nodes are often removed because they are enlarged. Morphological examination may, however, still be negative in cases where a limited number of tumor cells still might be present. In all these examples the present invention describes a means of detecting and selecting the target tumor cells for gene cloning purposes.

In addition to using cancer cells obtained from different tissues or organs in patients, the invention also describes another way of obtaining metastatic human tumor cells for use in the search for genes with site-specific expression. Cells from several human tumors have been grown *in vitro* or in immunodeficient animals *in vivo*, and such cells have been used to establish experimental metastasis models or models in which the cells can be grown orthotopically, i.e. in the clinically relevant

tissues of origin; malignant melanoma in the skin; osteosarcoma in bone; colorectal cancer in the bowel wall; breast cancer in the mammary fat pad, etc. In experimental metastasis models different patterns of tumor spread can be seen, depending on the cell line, the route of cell injection, and the type of host used.

5 Commonly the metastasis patterns simulate that of the corresponding tumor type in the clinic. By using such models it becomes possible also to obtain tumor cells from metastatic sites not usually accessible in patients, such as the spinal cord and the brain tissue. Again, for gene cloning purposes it would be important to select the human tumor cells from the animal cells to avoid problems with genes
10 expressed in the normal host cells.

Previously it has been impossible to perform meaningful gene cloning experiments on specimens of solid tumors and metastases and on malignant cells in blood and bone marrow with the object of identifying genes with site-specific expression.

15 This is because a considerable fraction of solid tumors and metastases is not malignant cells but connective tissue supporting and growing in between the malignant cells, and which also contains blood vessels that provide the necessary supply of nutritional factors and oxygen to the tumor. It has not been regarded as possible to adequately separate tumor cells from the normal cells without including
20 an intermediate step of culturing the cells *in vitro*, involving manipulations to get rid of the normal cells. However, such *in vitro* cultivation would result in a selection of subpopulation of tumor cells in an environment quite different from the situation *in vivo*, thereby inducing significant changes in gene expression patterns. Therefore, for the purpose of identifying genes associated with the
25 metastatic process, cultivation of tumor cells from solid metastases cannot be used. Moreover, it has not been regarded of interest to persons known in the field of gene cloning to compare gene expression patterns in malignant cells in untreated solid primary and metastatic tumors. Furthermore, in samples of blood and bone marrow tumor cells, if at all present, constitute a very low fraction of the total number of
30 nucleated cells, and the malignant cells in blood and bone marrow have not been regarded of interest for gene cloning attempts. This is because the tumor cells could not be adequately separated from normal cells, and importantly also because people known in the art of gene cloning have not expected that such malignant cells were sufficiently different in gene expression patterns from those in the
35 parent tumors.

Cancer cells isolated from human tumors metastasizing to different and clinically relevant target tissues and organs in immunodeficient animals have not been used in attempts to identify tumor-associated genes with site-specific expression, simply

because such human tumor models are very rare, but importantly also because of the lack of methods to obtain pure populations of cancer cells.

5 The object of the present invention is therefore to provide a method by which target cells can be separated from a cell population in order to identify the gene sequences from the target cells in a specific cell population environment.

This object has been obtained by the present invention characterized by the enclosed claims.

10 Since the object of the invention is to identify genes expressed specifically during early stages of tumor dissimulation, the solid tumors and metastases should be small in size, and the malignant cells in blood and bone marrow should represent so-called micrometastatic disease, i.e. a limited a number of tumor cells should be
15 present. If possible, such tumor cells should be collected even in cases where said cells cannot be detected by conventional morphological examinations or with diagnostic procedures such as radiology and magnetic resonance imaging. Evidently, since such cells have not been recognizable they have not been of interest for gene cloning purposes. The use of immunomagnetic techniques permits
20 isolation of said malignant cells even when present in low numbers. Various methods for amplifying DNA and RNA sequences make gene cloning possible on such low numbers of malignant cells, provided that this cell population is sufficiently pure.

25 The positive selection of target tumor cells can be obtained by the use of per se known techniques, as described in patent application PCT/NO93/00136 (WO 94/07139) and in PCT/NO95/00052. Since in the present case the purity of the final target cell population is important, the immunomagnetic selection process may be performed more than once, or may be performed as a combination of
30 positive (with target-cell recognizing monoclonal antibodies) and negative (with antibodies that bind to unwanted cells) selection. These techniques have been successfully used to isolate target cells from blood, bone marrow, malignant effusions, and from single cell suspensions prepared from solid tumor tissue of primary tumors and lymph node and other metastases. Similarly, the selection of
35 human malignant cells from normal stromal or hematopoietic cells in animal hosts has also been demonstrated, even in cases where the tumor cells resided in bone, bone marrow, the spinal cord or in brain tissue. Since one objective would be to search for genes with products involved in the early stages of metastasis formation it may happen that only relatively few tumor cells can be obtained, the purity of

which is particularly important. With this approach it is possible to obtain a better purified target cell population from patients and animal hosts than by any other known technique, providing unique possibilities for cloning genes with site-specific expression.

5

The next step of the invention involves the use of known gene cloning procedures, such as the use of the differential display procedure first described by Liang, A. and Pardee, A.B. (Science, Vol 257, 967-971, 1992). In this method, polymerase chain reactions are performed with enzymes and primers that give reverse transcription and random amplification of gene transcripts present in the target cells. Resulting cDNA fragments from the cell populations to be compared are thereafter studied on a sequencing gel and the site-specific fragments extracted and sequenced. Gene fragments of interest can then be further studied, including examination of their expression patterns in material similar to that used for cloning. Again, having access to purified tumor cell populations without irrelevant non-target cells interfering with the results is very important. The possibility of using human tumor cells isolated from metastasis models in immunodeficient animals is advantageous also because the models provide a reliable and continuous source of target tumor cells for extended studies. It is also important that the target cells, either from patients or from animal models, are isolated and treated for DNA and RNA studies directly and very rapidly to avoid unwanted alterations in gene expression not related to the objective of identifying genes with site-specific expression.

Different methods used for cloning new genes have their inherent limitations. The differential display-methods based on polymerase chain reaction techniques may suffer from problems related to representativity and reproducibility. With our approach we have consequently included steps aimed at minimizing such problems. This has been achieved mainly by the use of the immunobead selection technique which makes it possible to study specifically biologically representative cells, not only for the first differential display step, but also in the steps where the candidate genes are examined for expression levels in relevant cells and tissues.

35 Example 1:

Tumor cells from the primary tumor and axillary lymph nodes from a breast cancer patient were prepared by physical and enzymatic methods to obtain a single cell suspension. A bone marrow sample (50 ml) was aspirated and a peripheral blood sample was obtained by venous puncture, and the mononuclear cells from both

occasions were isolated on Lymphoprep (Nycomed Pharma, Oslo, Norway). The cell suspensions were independently incubated with the MOC-31 and BM7 monoclonal antibodies, recognizing a pan-epithelial antigen and the MUC-1 gene product, respectively. After washing and incubation Dynabeads M-450 SAM SD (Dyna, Oslo, Norway), which bind to the Fc-region of the primary antibodies, were added. Tumor cells with bound antibody-Dynabeads M-450 SAM SD complex could thereafter be isolated from the normal mononuclear cells by the use of a strong magnet. The nature of the selected cells was confirmed microscopically. From the different cell populations RNA was extracted and the material subjected to the differential display cloning procedure (Liang and Pardee, 1992), in which partial cDNA-sequences from mRNA subpopulations obtained by reverse transcription were amplified by polymerase chain reaction. Comparison of cDNA-fragments from the various tumor cell populations were compared on a sequencing gel, and fragments specifically expressed in cells obtained from one of the sites were extracted and sequenced. Among a number of interesting gene sequences with specific expression either in tumor cells isolated, with our magnetic immunobead technology, from bone marrow or in tumor cells immunomagnetically isolated from lymph node metastases, we have found one cell cycle related transcription factor, one oncogene product, in addition to genes not yet identified. The expression of the two identified gene sequences in biologically relevant model systems and clinical material is presently being analyzed.

Example 2:

In this example, cells from a model for experimental metastasis of a human breast cancer were used. In athymic, nude rats injection of MA-11 human breast cancer cells into the cisterna magna (CM) results in leptomeningeal spread and growth of the malignant cells. Moreover, MA-11 cells injected into the left cardiac ventricle (LV) form metastases in the spinal cord which result in the development of hind leg paralysis in the animals after approximately 35 days. Tumor cells from both locations were obtained by mincing the host tissue and preparing single cell suspensions, and the immunobead technique described under example 1 was used to positively select the malignant cells. Thereafter, RNA extraction of cells from the two sites, together with *in vitro* cultured MA-11 cells was performed and the material similarly subjected to the differential display cloning procedure as already described. In addition, mRNA extracted from relevant normal tissues in the rats were included as controls. It should be noted that the MA-11 cell line was established from micrometastatic tumor cells isolates with the immunomagnetic method from the bone marrow of a stage II breast cancer patient. Several candidate fragments specific for the cells growing in the leptomeninges or as metastases to

the spinal cord have been detected. Sequence analysis showed that these fragments represent both novel and known genes. Among the fragments confirmed as differentially expressed in MA-11 cells selected from metastatic cell, four candidate genes have so far been examined in more detail. Two of these, termed LV1 and LV12 are particularly interesting. LV1 shows very high expression selectivity in tumor cells from spinal cord metastases, whereas LV12 is downregulated in leptomeningeally growing cells. LV1 is found to be upregulated in a number of cell lines known to have a high capacity to form experimental metastasis in immunodeficient animals. In a panel of primary tumours from breast cancer patients, low expression of LV12 was related to short survival of the corresponding patients. Altogether the results show that LV1 mRNA seems to be upregulated in highly metastatic cells, and LV12 mRNA level was inversely correlated to progression and metastasis of breast cancer cells. Both genes are novel. In addition, a third promising candidate gene, CM13, is also a novel gene upregulated in tumor cells growing in the leptomeninges. Several other candidates are still to be further analyzed. For both LV1 and LV12 cDNA full length cloning has been initiated.

Example 3:

In a similar model to that described in example 2, MT1 human mammary cancer cells give rise to growth in the leptomeninges after CM injection, whereas LV injected cells metastasize to the bone marrow and bone in the vertebra of the spine and in the long bones. Cells from these two locations as well as *in vitro* grown cells have been isolated and RNA from the different cell populations has been extracted. Similar cloning procedures to those described in example 2 can be applied to this material.

Example 4:

Tumor cells isolated by the technique described in example 1 have been isolated from other breast cancer patients, from patients with colorectal cancers where the tumor cells were isolated from primary and recurrent tumors, from lymph nodes and liver metastasis, and blood and bone marrow samples, and from prostate cancer patients with cells selected from primary or recurrent tumor specimens, from lymph nodes in addition to specimens from blood and bone marrow. The isolated cells can be used for gene cloning purposes.

In addition to the use of the material described in examples 1-4 for gene cloning, it can be used for examining the expression patterns of all gene sequences of sufficient promise.

PATENT CLAIMS

1. Method for identifying genes with site-specific or site preferred expression in specific target cells present in a cell environment different or not from that of their origin,
- 5 **characterized in** that the target cells initially are detected and isolated by repeated immuno-magnetic procedures in order to obtain up to 100% specific target cells before exposing the said target cells to known gene cloning procedures. wherein unknown genes with differences in levels of mRNA expressions in the target cells isolated from different tissues, are compared.
- 10 2. Method according to claim 1, **characterized in** that the used target cells are malignant cells obtained from solid primary or recurrent tumors; and/or from metastases from such tumors to lymph nodes; and/or blood; and/or bone marrow; and/or bone tissue; and/or liver; and/or
- 15 lungs; and/or central nervous system; and/or malignant pleural effusions and ascites, urine; and/or cerebral spinal fluid; and/or other organ sites.
3. Method according to claims 1-2, **characterized in** that the malignant cells are isolated from single cell suspensions prepared from solid tumor manifestations; and/or from mononuclear cell fractions
- 20 obtained from bone marrow or blood samples; and/or from cells present in other body fluids.
4. Method according to claims 1-2, **characterized in** that the malignant cells used are *in vitro* cultivated human tumor cells; and/or human tumor cells grown in specific tissues in immunodeficient
- 25 animals; and/or experimental human tumor metastases in such animals.
5. Method according to claims 1-4, **characterized in** that RNA and/or DNA are extracted from the isolated cells.
- 30 6. Method according to claim 5, **characterized in** that the extracted nucleic acids are used for gene cloning purposes.
- 35

7. Method according to the above claims.

characterized in that the said gene cloning method is the differential display or the subtractive hybridization approaches, or any other procedure that can be used to identify genes with differential expression.

8. Method according to claim 7,

characterized in that amplified cDNAs obtained from malignant cells selected from different sites are studied and compared on sequencing gels, and where those with interesting site-specific or site-preferenced patterns are sequenced and identified.

9. Method according to claim 8,

characterized in that the expression patterns of identified gene sequences are studied on material obtained from all relevant tumor cell sites described in claims 1-4.

10. Method according to the preceding claims,

characterized in that previously unknown genes identified in preceding claims are used for gene therapy purposes, and/or as targets for procedures aimed at altering or inactivating the genes or their products.

11. Use of the method according to claim 1, to obtain specific gene sequences and their expression products in target cells present in cell environments different or not from their origin.

Attorney Docket No. 7885.56USWO

MERCHANT, GOULD, SMITH, EDELL, WELTER & SCHMIDT

United States Patent Application

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: IMMUNO-MAGNETIC CELL SEPARATION USED IN IDENTIFICATION OF GENES ASSOCIATED WITH SITE-PREFERENCED CANCER METHASTASIS FORMATION

The specification of which

- a. ☐ is attached hereto
b. ☒ was filed on as application serial no. and was amended on (if applicable) (in the case of a PCT-filed application) described and claimed in international no. PCT/NO97/00083 filed Intl Filing Date March 25, 1997 and as amended on (if any), which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (attached hereto).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

- a. ☐ no such applications have been filed.
b. ☒ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
Norway	961221	March 26, 1996	
ALL FOREIGN APPLICATION(S), IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

U.S. PROVISIONAL APPLICATION NUMBER	DATE OF FILING (Day, Month, Year)

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

Albrecht, John W.
Ansems, Gregory M.
Batzli, Brian H.
Beard, John L.
Berman, Charles
Black, Bruce E.
Blasdell, Thomas L.
Bogucki, Raymond A.
Bruess, Steven C.
Byrne, Linda M.
Canady, Karen S.
Carlson, Alan G.
Carter, Charles G.
Caspers, Philip P.
Chiapetta, James R.
Clifford, John A.
Daignault, Ronald A.
Daley, Dennis R.
Dalglish, Leslie E.
Daulton, Julie R.
DeVries Smith, Kate
DiPietro, Mark J.
Edell, Robert T.
Epp Ryan, Sandra
Farber, Michael B.
Funk, Steven R.
Glance, Robert J.
Golla, Charles E.
Gorman, Alan G.
Gould, John D.
Gregson, Richard
Gresens, John J.
Hamre, Curtis B.
Hillson, Randall A.
Johnston, Scott W.
Kastelic, Joseph M.
Kettelberger, Denise
Komanduri, Janaki
Kowalchyk, Alan W.
Kowalchyk, Katherine M.

Reg. No. 40,481
Reg. No. P-42,264
Reg. No. 32,960
Reg. No. 27,612
Reg. No. 29,249
Reg. No. 41,622
Reg. No. 31,329
Reg. No. 17,426
Reg. No. 34,130
Reg. No. 32,404
Reg. No. 39,927
Reg. No. 25,959
Reg. No. 35,093
Reg. No. 33,227
Reg. No. 39,634
Reg. No. 30,247
Reg. No. 25,968
Reg. No. 34,994
Reg. No. 40,579
Reg. No. 36,414
Reg. No. P-42,157
Reg. No. 28,707
Reg. No. 20,187
Reg. No. 39,667
Reg. No. 32,612
Reg. No. 37,830
Reg. No. 40,620
Reg. No. 26,896
Reg. No. 38,472
Reg. No. 18,223
Reg. No. P-41,804
Reg. No. 33,112
Reg. No. 29,165
Reg. No. 31,838
Reg. No. 39,721
Reg. No. 37,160
Reg. No. 33,924
Reg. No. 40,684
Reg. No. 31,535
Reg. No. 36,848

Lacy, Paul E.
Larson, James A.
Lasky, Michael B.
Lindquist, Timothy A.
Lynch, David W.
Marschang, Diane L.
McDaniel, Karen D.
McDonald, Daniel W.
McIntyre, Iain A.
Mueller, Douglas P.
Nasiedlak, Tyler L.
Nelson, Albin J.
Pauly, Daniel M.
Plunkett, Theodore
Pytel, Melissa J.
Reich, John C.
Reiland, Earl D.
Rittmaster, Ted R.
Schmaltz, David G.
Schuman, Mark D.
Schumann, Michael D.
Sebald, Gregory A.
Skoog, Mark T.
Soderberg, Richard
Sumner, John P.
Summers, John S.
Tellekson, David K.
Trembath, Jon R.
Underhill, Albert L.
Vandenburgh, J. Derek
Vradenburgh, Anna M.
Welter, Paul A.
Whipps, Brian
Williams, Douglas J.
Witt, Jonelle
Wood, Gregory B.
Wood, William J.
Xu, Min S.

Reg. No. 38,946
Reg. No. 40,443
Reg. No. 29,555
Reg. No. 40,701
Reg. No. 36,204
Reg. No. 35,600
Reg. No. 37,674
Reg. No. 32,044
Reg. No. 40,337
Reg. No. 30,300
Reg. No. 40,099
Reg. No. 28,650
Reg. No. 40,123
Reg. No. 37,209
Reg. No. 41,512
Reg. No. 37,703
Reg. No. 25,767
Reg. No. 32,933
Reg. No. 39,828
Reg. No. 31,197
Reg. No. 30,422
Reg. No. 33,280
Reg. No. 40,178
Reg. No. -P-43,352
Reg. No. 29,114
Reg. No. 24,216
Reg. No. 32,314
Reg. No. 38,344
Reg. No. 27,403
Reg. No. 32,179
Reg. No. 39,868
Reg. No. 20,890
Reg. No. P-43,261
Reg. No. 27,054
Reg. No. 41,980
Reg. No. 28,133
Reg. No. P-42,236
Reg. No. 39,536

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Merchant, Gould, Smith, Edell, Welter & Schmidt to the contrary.

Please direct all correspondence in this case to Merchant, Gould, Smith, Edell, Welter & Schmidt at the address indicated below:

Merchant, Gould, Smith, Edell,
Welter & Schmidt
3100 Norwest Center
90 South Seventh Street
Minneapolis, MN 55402-4131

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2	Full Name Of Inventor	Family Name Fodstad	First Given Name Oystein	Second Given Name
0	Residence & Citizenship	City Oslo	State or Foreign Country Norway NOX	Country of Citizenship Norway
1	Post Office Address	Post Office Address Frits Kiaers v. 28	City Oslo	State & Zip Code/Country N-0383 Norway
Signature of Inventor 201:			Date:	
2	Full Name Of Inventor	Family Name Hovig	First Given Name Johannes	Second Given Name Eivind
0	Residence & Citizenship	City Oslo	State or Foreign Country Norway NOX	Country of Citizenship Norway
2	Post Office Address	Post Office Address Sognsveien 31	City Oslo	State & Zip Code/Country N-0851 Norway
Signature of Inventor 202:			Date:	
2	Full Name Of Inventor	Family Name Engebraten	First Given Name Olav	Second Given Name
0	Residence & Citizenship	City Lorenskog	State or Foreign Country Norway NOX	Country of Citizenship Norway
3	Post Office Address	Post Office Address Haneborgsvn 43 A	City Lorenskog	State & Zip Code/Country N-1470 Norway
Signature of Inventor 203:			Date:	
2	Full Name Of Inventor	Family Name Ree	First Given Name Anne	Second Given Name Hansen
0	Residence & Citizenship	City Haslum	State or Foreign Country Norway NOX	Country of Citizenship Norway
4	Post Office Address	Post Office Address Kirkeveien 87 A	City Haslum	State & Zip Code/Country N-1344 Norway
Signature of Inventor 204:			Date:	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2	Full Name Of Inventor	Family Name Fodstad	First Given Name Oystein	Second Given Name
0	Residence & Citizenship	City Oslo	State or Foreign Country Norway	Country of Citizenship Norway
1	Post Office Address	Post Office Address Frits Kiaers v. 28	City Oslo	State & Zip Code/Country N-0383 Norway
Signature of Inventor 201:			Date: 23/9-98	
2	Full Name Of Inventor	Family Name Hovig	First Given Name Johannes	Second Given Name Eivind
0	Residence & Citizenship	City Oslo	State or Foreign Country Norway	Country of Citizenship Norway
2	Post Office Address	Post Office Address Sognsveien 31	City Oslo	State & Zip Code/Country N-0851 Norway
Signature of Inventor 202:			Date: 25/9-98	
2	Full Name Of Inventor	Family Name Engesbraten	First Given Name Olav	Second Given Name
0	Residence & Citizenship	City Lorenskog	State or Foreign Country Norway	Country of Citizenship Norway
3	Post Office Address	Post Office Address Haneborgsvn 43 A	City Lorenskog	State & Zip Code/Country N-1470 Norway
Signature of Inventor 203:			Date: 24/9/98	
2	Full Name Of Inventor	Family Name Ree	First Given Name Anne	Second Given Name Hansen
0	Residence & Citizenship	City Haslum	State or Foreign Country Norway	Country of Citizenship Norway
4	Post Office Address	Post Office Address Kirkeveien 87 A	City Haslum	State & Zip Code/Country N-1344 Norway
Signature of Inventor 204:			Date: 26/9-98	

§ 1.56 Duty to disclose information material to patentability.

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim;

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

(1) Each inventor named in the application;

(2) Each attorney or agent who prepares or prosecutes the application; and

(3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.